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Abstract
Background: Open spina bifida (OSB) is one of the most common congenital central nervous system defects and
leads to long-term physical and cognitive disabilities. Open fetal surgery for OSB improves neurological outcomes
and reduces the need for ventriculoperitoneal shunting, compared to postnatal surgery, but is associated with a
significant risk of prematurity and maternal morbidity. Fetoscopic surgery comes with less maternal morbidity, yet
the question remains whether the procedure is neuroprotective and reduces prematurity. Comparison of outcomes
between different treatment options is challenging due to inconsistent outcome reporting. We aim to develop and
disseminate a core outcome set (COS) for fetal OSB, to ensure that outcomes relevant to all stakeholders are
collected and reported in a standardised fashion in future studies.
Methods: The COS will be developed using a validated Delphi methodology. A systematic literature review will be
performed to identify outcomes previously reported for prenatally diagnosed OSB. We will assess maternal (primary
and subsequent pregnancies), fetal, neonatal and childhood outcomes until adolescence. In a second phase, we
will conduct semi-structured interviews with stakeholders, to ensure representation of additional relevant outcomes
that may not have been reported in the literature. We will include patients and parents, as well as health
professionals involved in the care of these pregnancies and children (fetal medicine specialists, fetal surgeons,
neonatologists/paediatricians and allied health). Subsequently, an international group of key stakeholders will rate
the importance of the identified outcomes using three sequential online rounds of a modified Delphi Survey. Final
agreement on outcomes to be included in the COS, their definition and measurement will be achieved through a
face-to-face consensus meeting with all stakeholder groups. Dissemination of the final COS will be ensured through
different media and relevant societies.
Discussion: Development and implementation of a COS for fetal OSB will ensure consistent outcome reporting in
future clinical trials, systematic reviews and clinical practice guidelines. This will lead to higher quality research,
better evidence-based clinical practice and ultimately improved maternal, fetal and long-term childhood outcomes.
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Background
Open spina bifida (OSB) is a common birth defect, com-
plicating approximately 5 in every 10,000 births [1–3].
The condition occurs when the lower segments of the
neural tube do not close properly early in embryonic life.
As a result, the fetal meninges and the nerve elements
are exposed at the level of the fetal back. The condition
is not lethal and, with access to multidisciplinary
prenatal and postnatal care, 1-year survival rates are 88–
96% [2, 4]. However, progressive damage to the exposed
neural elements in utero results in distal spinal cord and
nerve dysfunction. Moreover, progressive leakage of
cerebrospinal fluid through the defect causes hindbrain
herniation (Chiari 2 malformation) and ventriculomegaly/
hydrocephalus [5]. Clinically, this presents as impaired
lower limb function (ambulation problems), bowel and
bladder dysfunction (constipation and incontinence) and
sexual dysfunction postnatally. About 15% of cases will
have decreased cognitive function, in part due to compli-
cations of ventriculo-peritoneal shunt placement, which is
often required postnatally to relieve the increased intra-
cranial pressure resulting from the hydrocephalus [3, 6].
Historically, the spinal lesion was closed surgically
shortly after birth (postnatal repair), but fetal repair is
now becoming the state-of-the-art treatment as it improves
functional outcomes [7–11]. Indeed, in 2011, the Manage-
ment of Myelomeningocele Study (MOMS), a randomised
controlled trial comparing prenatal to postnatal repair,
demonstrated that in-utero closure resulted in a reversal of
hindbrain herniation in two thirds of cases, halved the need
for ventriculoperitoneal shunting and improved motor
function. However, fetal surgery comes at the cost of an
increased risk of maternal morbidity, preterm rupture of
membranes and preterm delivery [12].
The MOMS trial utilised a hysterotomy-based ap-
proach for prenatal repair, also referred to as ‘open’
fetal surgery, but subsequent minimally invasive (feto-
scopic) approaches have been developed in an attempt
to minimise fetal and maternal morbidity [13, 14].
Given the rapid developments in prenatal interven-
tions, there is a need for robust evidence on the safety
and efficacy of these therapies [15]. The literature to
date reports varying outcomes, which makes it hard to
compare results or synthesise the data from multiple
studies, thereby limiting the value of this research in
providing guidance to clinical practice.
Core outcome sets (COS) are well-defined, disease-
specific, standardised groups of outcome measures that
should be recorded and reported in all trials [16]. The
development of COS is supported by the Core Outcome
Measures in Effectiveness Trials initiative (COMET)
(www.comet-initiative.org) and further promoted in
women’s health by the Core Outcomes in Women’s and
Newborn’s Health (CROWN) initiative [17]. COSs in
women’s health have now been established for many dis-
ease conditions, with demonstrable clinical benefits [18].
Our goal is to develop, disseminate, and implement a
core outcome set for prenatally diagnosed spina bifida
that incorporates the views of key stakeholders including
health professionals, researchers, parents and children.
Methods
Overview
The methods for the development of the Core Outcome
Set for Myelomeningocele (COSMiC) are informed by
the recommendations of the COMET initiative and the
Core Outcome Set–STAndards (COS-STAD), with
adaptations specific to the scope of this project [19, 20].
We will use a step-wise approach, consisting of four
stages, as shown in Fig. 1. Step 1 will be to identify cur-
rently reported outcomes in the literature and identify
unreported outcomes important to patient/parent stake-
holders, through structured interviews. Step 2 will be a
modified three-phase online Delphi process to determine
the core outcomes important to all stakeholders. Step 3
will be a face-to-face consensus meeting of key stakeholders
to agree on the COS, and step 4 will be dissemination and
implementation of the developed COS.
Study registration
The study has been registered with the COMET initiative
(www.comet-initiative.org; # 1187) and the International
Prospective Register of Systematic Reviews (PROSPERO; #
CRD42018104880). The systematic review will be con-
ducted in accordance with guidance set out by the PRISMA
Statement for reporting systematic reviews and meta-
analyses of studies that evaluate health care interventions.
Scope of the core outcome set
This core outcome set will apply to all pre- and perinatal
interventions for prenatally diagnosed OSB. We will
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include outcome measures related to maternal, fetal,
neonatal and childhood outcomes.
Systematic review to identify potential core outcomes
We will conduct and publish a systematic review to
identify what outcomes have previously been reported
for prenatally diagnosed OSB. Studies reporting on fetal
surgery, termination of pregnancy and/or postnatal
repair will be included. We will include randomised
controlled trials and observational retrospective and
prospective studies. We will exclude case reports, case
series including less than 20 cases, editorials, letters to
the editor and review articles. All outcomes reported in
the studies will be considered.
Our search strategy was designed by an experienced
librarian (DH) and contains variations on the following
MeSH terms: Meningomyelocele, myelocele, myelome-
ningocele, Spinal dysraphism, spina bifida cystica,
meningocele, fetus, pregnancy, in-utero, intra-uterine,
antenatal, prenatal, fetal diseases, fetal therapies and pre-
natal diagnosis. We will search the databases EMBASE,
MEDLINE, CINAHL, PubMed and ClinicalTrials.gov
from inception to September 2019. No data or language
limits will be applied. Two reviewers (SA and CW) will
individually screen all titles and abstracts of identified
manuscripts. The full-text articles will be reviewed for
all studies that meet the inclusion criteria, in addition to
the studies where inclusion cannot be decided based
solely on the abstract or title. The articles will be
assessed for eligibility based on a critical review of the
studies’ full text and any conflicts between the reviewers
will be resolved through dialogue and arbitration by a
third reviewer (TVM), should this be necessary. Reference
management will be done with DistillerSR (Evidence
Partners, Ottawa, Canada).
Data will be extracted using a predesigned and trialled
proforma. The following information will be included
for each study: study design, year of study, journal,
sample size, setting, participants, interventions (if any),
outcomes, outcome measurement tools and timing of
outcome measurement.
All identified outcomes will be collated into an outcome
inventory and organised into the following categories:
maternal (primary and subsequent pregnancies), fetal,
neonatal and childhood to adolescence. The outcomes will
be reviewed by the steering committee to reduce duplica-
tion and ensure the final inventory is succinct and clear.
The steering group will consist of fetal medicine special-
ists, fetal surgeons (obstetricians, neurosurgeons and
paediatric surgeons), neonatologists and developmental
paediatricians, allied health specialists, as well as a group
of patient participants. The inventory will be entered into
the modified Delphi process.
Patient and stakeholder involvement
Patient, parent and carer expertise is crucial for the
development of COSs. Patient participants frequently
identify outcomes that may not be considered clinically
relevant by health professionals or not yet recognised in
the existing literature. Semi-structured qualitative inter-
views will be performed with patients, parents and carers
affected by prenatally diagnosed OSB to identify patient
reported outcomes and outcome domains [19]. A
minimum of two groups of parents will be included:
those who underwent prenatal OSB repair and those
who continue the pregnancy with a postnatal repair.
Fig. 1 Stages for developing a Core Outcome Set for prenatally diagnosed Myelomeningocele (COSMiC)
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Interviews will be audio-recorded, transcribed and ana-
lysed for content. Patient participants will also be asked
to assess the words, phrases and language used to define
and describe conditions, interventions and outcomes to
be included in the Delphi process. Similar semi-structured
interviews will also be held with other aforementioned
stakeholders.
Determining core outcomes
The core outcomes will be determined using a modified
Delphi technique [21]. Electronic questionnaires will be
used to facilitate international consensus building. We
will include Delphi participants across all involved stake-
holder groups. Potential experts will be identified by
members of the steering committee who represent a
diverse and international field of expertise. Experts from
established and experienced centres that perform both
prenatal and postnatal repair and regularly publish their
results, as well as those where only postnatal repair is of-
fered, will be invited to participate. Additional invitations
will be extended to national and international profes-
sional organisations to advertise the study and encourage
additional participation, as well as through social media.
International coverage will be prioritised and will be
facilitated by the international representation of the steering
group (North America, Europe, Middle East, Asia/Pacific).
Patient participants will be invited from fetal and paediatric
centres specialising in prenatal diagnosis and treatment of
OSB, as well as through patient support groups.
Participants will be sent a plain language information
summary of the study, explanation of the Delphi process
and further instructions on how to participate. Partici-
pants will be asked to forward the invitation to other
potential participants with expertise in the field. Once
the participants register and consent to participate, they
will complete an online demographic survey and be
asked to self-identify with the most appropriate stake-
holder group. Participants who fail to complete all three
rounds will be asked for their reason for withdrawal.
Delphi process
There will be three online sequential rounds of the
Delphi process. Questionnaires will be completed using
DelphiManager, a web-based system for management of
Delphi surveys (COMET Initiative, University of Liver-
pool, UK). Each participant will be given a unique identi-
fier that will be used throughout the process and ensure
anonymity is maintained. In each round, participants will
be sent a link to the questionnaire and their responses
collated and analysed for future rounds.
First round
The first round will ask participants to rate each of the
outcomes using a 9-point Likert scale where typically 1–
3 signifies an outcome that is of minor importance or
relevance, 4–6 is important but not critical, while 7–9
signified a critical outcome [22]. We will also include an
‘unable-to-score’ category for those participants who feel
they may not have the expertise to assess certain out-
comes. The outcomes will be grouped under relevant
headings and categories (maternal, fetal, neonatal, child-
hood). Participants in this round will also be encouraged
to include ‘new’ outcomes that they would consider rele-
vant for inclusion but which have not previously been
identified. Explanations of the outcomes in lay terms will
be included where necessary. The survey will remain
open for 6 weeks with biweekly reminders to encourage
completion of the survey. At the end of the round, indi-
vidual answers will be aggregated and summarised. New
outcomes will be considered and potentially approved by
the Steering Group for inclusion in the second round.
Second round
Only participants who completed round one will be in-
vited to complete round two. All outcomes from round
one in addition to the new approved outcomes provided
by the participants will be included in the second round.
Each participant will receive the rating of each outcome
for individual responses, as well as summative responses
for each stakeholder group and the total group overall.
Participants will be asked to re-rate the outcomes
using the same Likert scale as in round one, with the
knowledge of their previous response and with the
knowledge of other stakeholders’ ratings. Participants
may change their ratings if they consider that rescoring
is more appropriate or retain their original score.
Prior to submission of the round two responses,
participants will be asked if they are interested in partici-
pating in the face-to-face consensus meeting after round
three.
Third round
Participants who completed round two will be presented
with the results of the previous round at the individual,
stakeholder and overall group level and asked to accept
or reject those were consensus was reached. We are de-
fining ‘consensus’ as an outcome that at least 70% of the
panel members have rated as critically important (7–9)
and less than 15% have rated as not important (1–3)
[23]. Outcomes will additionally be classified as ‘consen-
sus out’ if > 70% participants rated it 1–3 and < 15%
rated it 7–9. Outcomes which fulfil these criteria at the
conclusion of the final round will move on to the
consensus meeting. There is currently no universally ac-
cepted definition of consensus as to which scores on the
9-point scale indicate items that should be brought to a
COS consensus meeting, but recent COSs, including in
women’s health research, have used similar definitions
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[24, 25]. Willingness to participate in the face-to-face
meeting will be confirmed.
Stakeholder consensus
Participants who complete all three phases of the Delphi
process and express an interest to attend will be invited
to the consensus meeting. Our aim is to involve 2–5
representatives from each of the stakeholder groups.
Should important stakeholders be unable to attend in
person, electronic meeting software will be used. Discus-
sions will be led by an experienced moderator to ensure
the meeting is collaborative, inclusive and productive.
The main objective of the meeting will be to approve the
final COS from the Delphi process and address outcomes
where consensus was not previously reached. Each of the
outcomes not reaching consensus will be discussed and a
final vote on their inclusion/exclusion performed anonym-
ously and electronically.
Measuring core outcomes
Once the final COS has been agreed upon, we will reach
consensus on how and when the outcomes should be
measured. Potential outcome definitions will then be
discussed and agreed upon at the consensus meeting
based on data from our systematic review. Measurement
methods will be assessed for quality based on the frame-
work of the Consensus-based Standards for the selection
of health Measurement Instruments (www.cosmin.nl).
COSMIN evaluates outcome measures according to
their validity, reliability, responsiveness and interpret-
ability [26]. If the final outcomes were not identified in
our systematic review, we will conduct an additional
electronic search exercise to determine the most appro-
priate measurement tool(s).
Dissemination and implementation
We will collaborate with researchers and journal editors
from relevant maternal-fetal medicine, surgical and
paediatric fields to distribute and implement the COS as
widely as possible. We plan on presenting the COS at
national and international meetings and publishing in
peer reviewed journals endorsed by the CROWN initiative
and relevant to the key stakeholder groups. The CROWN
initiative and Cochrane Pregnancy and Childbirth Group
endorse COS and expect future authors to report their
study results according to the COS, rather than non-core
or surrogate outcomes [17]. We will also disseminate it
further through press-releases, newsletters and events to
raise awareness of its development especially amongst par-
ent/patient organisations. We will engage with Cochrane
Review Groups, clinical guideline developers, research
funders and regulators and trial registries to support its
implementation. Our protocol and its results will be
archived in COMET and CROWN databases to aid ease
of accessibility for future studies on prenatally diagnosed
OSB [26].
Discussion
Rapid advances in prenatal diagnosis and fetal surgery
highlight the need for the development and implementa-
tion of a standardised core outcome set for prenatally
diagnosed OSB. This COS will be vital to guide the
design of future clinical trials and reporting on novel
surgical techniques. Involvement of parents and patients
affected by prenatally diagnosed OSB will ensure that
the COS will be clinically relevant and wide-reaching. It
will allow the effective standardisation and harmonisa-
tion of data for systematic reviews and meta-analyses
and ultimately improve clinical practice and patient care.
We hope that the principles of this COS may also guide
further research in other areas of fetal surgery that are
currently being developed.
Trial status
The systematic review part of this study has been regis-
tered with the International prospective register of
systematic reviews (Prospero) on December 5, 2018,
with study number CRD42018104880 and started on
January 1, 2019. Data collection is complete and analysis
is ongoing. Stakeholder interviews will start in the fall of
2020. The Delphi process will follow, with completion
expected by June 2021.
This is the first version of the protocol.
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